Blake E. Smith

Blake E. Smith

Auto-generated profile, based on publicly available information

Blake E. Smith

Koch Institute for Integrative Cancer Research; Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Cell Chemical Biology
Verified
Journal Article
Closed access
DBDaniel P. Bondeson
Daniel P. Bondeson
BSBlake E. Smith
Blake E. Smith
GBGeorge M. Burslem
George M. Burslem
ABAlexandru D. Buhimschi
Alexandru D. Buhimschi
JHJohn Hines
John Hines
CCCraig M. Crews
Craig M. Crews

1 January 2018 in Cell Chemical Biology
Verified
Journal Article
Closed access
GBGeorge M. Burslem
George M. Burslem
BSBlake E. Smith
Blake E. Smith
ALAshton Lai
Ashton Lai
SJSaul Jaime-Figueroa
Saul Jaime-Figueroa
DMDaniel C. McQuaid
Daniel C. McQuaid
CCCraig M. Crews
Craig M. Crews

10 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBlake E. Smith
Blake E. Smith
SWStephen L. Wang
Stephen L. Wang
SJSaul Jaime-Figueroa
Saul Jaime-Figueroa
AHAlicia Harbin
Alicia Harbin
JWJing Wang
Jing Wang
CCCraig M. Crews
Craig M. Crews
PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many potent PROTACs with specificity for dissimilar targets have been developed; however, the factors governing degradation selectivity within closely-related protein families remain elusive. Here, we generate isoform-selective PROTACs for the p38 MAPK family using a single warhead (foretinib) and recruited E3 ligase (von Hippel-Lindau). Based on their distinct linker attachments and lengths, these two PROTACs differentially recruit VHL, resulting in degradation of p38α or p38δ. We characterize the role of ternary complex formation in driving selectivity, showing that it is necessary, but insufficient, for PROTAC-induced substrate ubiquitination. Lastly, we explore the p38δ:PROTAC:VHL complex to explain the different selectivity profiles of these PROTACs. Our work attributes the selective degradation of two closely-related proteins using the same warhead and E3 ligase to heretofore underappreciated aspects of the ternary complex model.

15 May 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJaya Sangodkar
Jaya Sangodkar
APAbbey Perl
Abbey Perl
RTRita Tohme
Rita Tohme
JKJanna Kiselar
Janna Kiselar
DKDavid B. Kastrinsky
David B. Kastrinsky
GNGoutham Narla
Goutham Narla
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attention as an alternative targeted approach. Here, we have demonstrated that activation of the tumor suppressor protein phosphatase 2A (PP2A), a negative regulator of multiple oncogenic signaling proteins, is a promising therapeutic approach for the treatment of cancers. Our group previously developed a series of orally bioavailable small molecule activators of PP2A, termed SMAPs. We now report that SMAP treatment inhibited the growth of KRAS-mutant lung cancers in mouse xenografts and transgenic models. Mechanistically, we found that SMAPs act by binding to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. These results show that PP2A can be activated in cancer cells to inhibit proliferation. Our strategy of reactivating endogenous PP2A may be applicable to the treatment of other diseases and represents an advancement toward the development of small molecule activators of tumor suppressor proteins.

8 April 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
CDConnor S. Dobson
Connor S. Dobson
ARAnna N. Reich
Anna N. Reich
SGStephanie Gaglione
Stephanie Gaglione
BSBlake E. Smith
Blake E. Smith
EKEllen J. Kim
Ellen J. Kim
MBMichael E. Birnbaum
Michael E. Birnbaum

4 March 2026 in Nature
Verified
Journal Article
Closed access
PDF file
MCMonica Cassandras
Monica Cassandras
XSXavier Sanchez
Xavier Sanchez
LHLauren Hsu
Lauren Hsu
YHYu Huang
Yu Huang
AGAdam J. Getzler
Adam J. Getzler
JAJudith Agudo
Judith Agudo